What is DSN?
DSN operates at the intersection of clinical precision and administrative agility. Its flagship product, Endo-Exec, and the broader v20 software suite are engineered to address the complex requirements of modern dental and specialty practices. By leveraging cloud-based architecture, DSN enables practitioners to manage drug interactions, insurance eligibility, and claims processing from any location with internet access. This focus on interoperability allows practices to maintain their preferred software ecosystems while benefiting from a centralized, high-performance management platform. The company's market position is defined by its ability to bridge the gap between diagnostic device data and practice management workflows, effectively transforming how specialized medical offices structure their daily operations.
How much funding has DSN raised?
DSN has raised a total of $467K across 2 funding rounds:
Debt
$150K
Debt
$317K
Debt (2020): $150K with participation from PPP
Debt (2021): $317K led by PPP
Key Investors in DSN
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for DSN?
With this latest infusion of capital, DSN is well-positioned to accelerate its product roadmap and expand its reach within the dental and specialty healthcare markets. The company's strategic focus will likely center on deepening its cloud-native capabilities and further refining its diagnostic integration tools. As the healthcare industry continues to shift toward digitized, remote-accessible workflows, DSN's emphasis on flexibility and choice provides a significant competitive advantage. Future growth initiatives are expected to prioritize the enhancement of its multi-specialty support, ensuring that DSN remains the software of choice for practices that demand high-level precision and seamless technological synergy.
See full DSN company page
